Sleep apnea syndrome in patients with methadone or buprenorphine.

OBJECTIVES

This work aimed to assess the association between sleep apnea syndrome (SAS) and opioid substitution treatments (OST) dose/timing of administration in patients receiving methadone or buprenorphine for an opioid use disorder (OUD).

METHODS

We conducted a retrospective cross-sectional study by including files of adult patients treated between November 2015 and January 2023 with methadone or buprenorphine and who had a nocturnal respiratory polygraphy. We collected information on treatments and polygraphical recording data such as the apnea-hypopnea index (AHI).

RESULTS

We enrolled 60 patients on methadone and 15 on buprenorphine. The sample encompassed 72% of males, and the mean age was 36±7.49years. Moderate to severe and severe SAS were significantly associated with the daily dose and the evening administration but was not predicted by the type of OST. However, the mean and median values of AIH were significantly greater with methadone. Contrary to methadone, there was no significant correlation between the buprenorphine daily dose and the AHI. The best sensitivities and specificities for the prediction of an AHI≥15 events/h and an AHI≥30 events/h were respectively obtained with methadone dose thresholds of 77.5mg/day.

CONCLUSIONS

In this sample, the methadone daily dose of 77.5mg was the best cut-point to predict moderate to severe SAS, especially while taken in the evening, and we found no correlation between buprenorphine and the AHI. These results draw clinicians' attention to buprenorphine use as an alternative for patients treated with methadone and having SAS.